Drug Profile


Alternative Names: CMSO2EN2

Latest Information Update: 31 Oct 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nonindustrial source
  • Class Antineoplastics; Nitrosourea compounds; Small molecules
  • Mechanism of Action Alkylating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cancer; Colorectal cancer; Glioma; Head and neck cancer; Malignant melanoma; Renal cancer; Sarcoma

Most Recent Events

  • 23 Mar 2000 A phase II study in melanoma has been added to the therapeutic trials and adverse events sections
  • 03 Aug 1999 Preclinical studies have been added to the pharmacodynamics section
  • 19 May 1997 Phase-II clinical trials for Glioma in France (Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top